XORTX Will Seek FDA Approval for Gout Drug in 2026
The company plans to submit an application for its new gout treatment to the FDA in late 2026.
Updated on Sept. 18, 2026 in Arthritis
Live Poll
Should pharmaceutical companies prioritize developing new treatments for common conditions like gout?
XORTX Therapeutics plans to submit an Investigational New Drug application to the FDA for its XRx-026 gout program in the fourth quarter of 2026. This move initiates the regulatory path for a proprietary oxypurinol formulation designed to serve patients who struggle with existing therapies.
Why it matters
The company aims to provide a new therapeutic option with a safety and efficacy profile that improves upon current xanthine oxidase inhibitors. This development addresses a significant medical need for the millions of Americans managing gout and complications from high uric acid.
Approximately 3-5 percent of patients cannot tolerate allopurinol, a common treatment. The company estimates that the XRx-026 program addresses a US$700 million annual U.S. market opportunity.
The players
XORTX Therapeutics
This clinical pharmaceutical company is headquartered in Calgary and focuses on developing therapies for progressive kidney disease and gout.
FDA
The Food and Drug Administration is the federal agency responsible for regulating new drug applications and clinical study protocols in the United States.
The details
XORTX Therapeutics intends to conduct a two-part clinical study to assess the pharmacokinetics and efficacy of its proprietary XORLO formulation. Following this, the company targets a New Drug Application submission approximately one year after the initial FDA filing.
Timeline
XORTX anticipates submitting an IND to the FDA in the fourth quarter of 2026.
The company targets an NDA submission in September 2027.
Global gout cases are expected to increase 70 percent over the next 25 years.
The Big Picture
XORTX Therapeutics is positioning its new drug to compete in a market segment where established xanthine oxidase inhibitors, such as febuxostat, have previously demonstrated significant commercial success by generating over $450 million in annual sales.
The development of XRx-026 could provide a new therapeutic pathway for the 3-5 percent of gout patients who are currently unable to tolerate standard treatments like allopurinol. This could eventually shift the standard of care for those suffering from chronic gout symptoms.
The takeaway
Advancements in gout treatment reflect the growing demand for specialized pharmaceuticals as the prevalence of the condition continues to rise. Patients currently struggling with existing medications should consult with their healthcare providers regarding upcoming clinical trial availability.
Further reading
For more information on current treatment landscapes, visit the Arthritis section.
Source note: This article includes information reported by Firstwordpharma.
Live Poll
Should pharmaceutical companies prioritize developing new treatments for common conditions like gout?
